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Km and Vmax valuesStructural analyses of bacterial ATP-binding-cassette transporters revealed that the glutamine residue in Q-
loop plays roles in interacting with: 1) a metal cofactor to participate in ATP binding; 2) a putative catalytic
water molecule to participate in ATP hydrolysis; 3) other residues to transmit the conformational changes
between nucleotide-binding-domains and transmembrane-domains, in ATP-dependent solute transport. We
have mutated the glutamines at 713 and 1375 to asparagine, methionine or leucine to determine the
functional roles of these residues in Q-loops of MRP1. All these single mutants signiﬁcantly decreased
Mg·ATP binding and increased the Km (Mg·ATP) and Vmax values in Mg·ATP-dependent leukotriene-C4
transport. However, the Vmax values of the double mutants Q713N/Q1375N, Q713M/Q1375M and Q713L/
Q1375L were lower than that of wtMRP1, implying that the double mutants cannot efﬁciently bind Mg·ATP.
Interestingly, MRP1 has higher afﬁnity for Mn·ATP than for Mg·ATP and the Mn·ATP-dependent
leukotriene-C4 transport activities of Q713N/Q1375N and Q713M/Q1375M are signiﬁcantly higher than
that of wtMRP1. All these results suggest that: 1) the glutamine residues in Q-loops contribute to ATP-binding
via interaction with a metal cofactor; 2) it is most unlikely that these glutamine residues would play crucial
roles in ATP hydrolysis and in transmitting the conformational changes between nucleotide-binding-domains
and transmembrane-domains.ATP binding cassette; P-gp, P-
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Over-expression of ATP-binding cassette (ABC) transporters, such
as P-glycoprotein (P-gp or ABCB1) [1–3], breast cancer resistance
protein (BCRP or ABCG2) [4,5] and/or multidrug resistance protein
(MRP1 or ABCC1) [6,7], confers acquired multidrug resistance (MDR)
owing to the fact that these ABC transporters catalyze ATP-dependentanticancer drug transport. Although some of the ABC transporters,
such as ABCG2, contain one nucleotide binding domain (NBD) and
one transmembrane domain (TMD), these transporters are thought to
form either a homo- or a hetero-dimer in the plasma membrane [8–
11]. Thus, all the functional ABC transporters contain two NBDs and at
least two TMDs [3,7–12]. UponMg·ATP binding, the two NBDs form a
dimer in which the two Mg·ATP molecules are each sandwiched
between the Walker A motif from one NBD and the LSGGQ ABC
signature motif from another [13–19]. In addition, the residues from
Walker B motif, A-loop, D-loop, H-loop and Q-loop [13,14,16,17,19–
36] also contribute to Mg·ATP binding and hydrolysis. Detailed
structural analyses of several NBDs of ABC transporters revealed that
the amide ε-oxygen of glutamine residue in Q-loop, as shown in Fig.
S1, participates in Mg·ATP binding by interacting, together with
other ﬁve oxygen atoms from the Walker A serine residue, the β- and
γ-phosphate of the bound ATP and two water molecules, with a Mg++
cofactor to form the octahedral coordination geometry
[13,16,21,25,27,29]. The amide ε-nitrogen of the glutamine residue in
Q-loop may interact with the putative hydrolytic water molecule in the
active center [13], implying that this residue may play a role in ATP
hydrolysis. In addition, the amide ε-nitrogen of the glutamine residue in
Q-loop may also interact with an amino acid from another NBD [13] to
stabilize theNBD·ATP·ATP·NBDsandwich structure. Furthermore,the
residues around the glutamine residue (in the linear sequence of an
1791R. Yang et al. / Biochimica et Biophysica Acta 1808 (2011) 1790–1796NBD) in Q-loop form a Q-loop cleft that interacts with the residues in L-
loop of the transmembrane subunits [14,17], suggesting that these
interactions may facilitate inter-domain communications between the
transport-substrate-binding sites, such as TMDs, and ATP binding/
hydrolysis sites, such as NBDs [13,14,22]. Thus, the interactions of the
glutamine residue in Q-loop with the residues mentioned above may
playvery important roles inATPbinding, hydrolysis andATP-dependent
solute transport. However, whether the glutamine residue in Q-loop of
human MRP1 will play so many important roles has not been
experimentally proved yet. In order to determine the functional roles
of the glutamine residue in the Q-loop of human MRP1, we have
substituted the glutamine residue in Q-loop of MRP1 with: 1) an
asparagine (Q713N and Q1375N) that remains the amide group but
with one methylene shorter in asparagine than in glutamine; 2) a
methionine (Q713M andQ1375M) that eliminates the amide group but
contains paired electrons in the sulfur atom of the methionine residue
that might potentially interact with the Mg++ cofactor; 3) a leucine
(Q713L and Q1375L) that eliminates the amide group and abolishes the
interactions with Mg++ cofactor and the putative hydrolytic water
molecule, and used them to determine the consequence of these
mutations in ATP-dependent leukotriene C4 (LTC4) transport. The data
presented in this manuscript indicate that the glutamine residues in the
Q-loops of MRP1 mainly play a role in Mg·ATP binding, but not in ATP
hydrolysis and in inter-domain communications between the NBDs and
TMDs.
2. Materials and methods
2.1. Materials
Sodium orthovanadate, EGTA and ATP were purchased from
Sigma. [14,15,19,20-3H]-leukotriene C4 was from PerkinElmer Life
Sciences. [α-32P]-8-N3ATP and [γ-32P]-8-N3ATP were from Afﬁnity
Labeling Technologies. Fetal bovine serum was from Gemini Bio-
Products. QuikChange site-directed mutagenesis kit was from
Stratagene. Anti-mouse Ig conjugated with horseradish peroxidase
was from Amersham Biosciences. Chemiluminescent substrates for
western blotting were from Pierce.
2.2. Site-directed mutagenesis of human MRP1 cDNA
WtN-half (NH, 1–932) and C-half (CH, 933–1531) of humanMRP1
cDNA cloned into pDual expression vector [37,38], named as pDual/
NH/CH, was used as a template for the in vitro mutagenesis. The
glutamine residue at position of 713 in Q-loop of NBD1 or 1375 in Q-
loop of NBD2 was mutated to either asparagine (N), methionine (M)
or leucine (L) by using the forward and reverse primers and the
QuikChange site-directed mutagenesis kit [39]. The forward and
reverse primers used to introduce thesemutations are: Q713/forward,
5′-TCC GTG GCC TAT GTG CCA XXX CAG GCC TGG ATT CAG AAT-3′;
Q713/reverse, 5′-ATT CTG AAT CCA GGC CTG XXX TGG CAC ATA GGC
CAC GGA-3′; Q1375/forward, 5′-AAG ATC ACC ATC ATC CCC XXX GAC
CCT GTT TTG TTT TCG GG-3′; Q1375/reverse, 5′-CC CGA AAA CAA AAC
AGG GTC XXX GGG GAT GAT GGT GAT CTT-3′. The underlined XXX
sequences are codons for mutated residues as shown in Table S1.
Regions containing these mutations were sequenced to conﬁrm that
the correct clones were obtained. Recombinant viral DNA preparation
and baculovirus viral particle production were carried out according
to the procedures described [38].
2.3. Cell culture and cells expressing N-half and C-half of MRP1
Spodoptera frugiperda 21 (Sf21) cells were cultured in Grace's
insect cell medium supplemented with 5% heat-inactivated fetal
bovine serum at 27 °C. Viral infection was performed according to
Invitrogen's recommendations, i.e., a multiplicity of infection (MOI) of5 to 10 was used to infect the insect cells. The expression levels of the
dually expressed N-half and C-half with varying MOI were deter-
mined by western blot analysis. The MOI producing similar amount of
N-half (by comparing the wt N-half with the mutated N-half) and C-
half (by comparing thewt C-half with themutated C-half) was used to
infect Sf21 cells for membrane vesicle preparations.
2.4. Identiﬁcation of N-half and C-half of MRP1 protein
Western blot was performed according to the method described
previously [39]. A 42.4 mAbwas used to identify the NBD1-containing
N-half fragment of MRP1, whereas 897.2 mAb was used to detect the
NBD2-containing C-half fragment [37,39]. The secondary antibody
used was anti-mouse Ig conjugated with horseradish peroxidase.
2.5. Membrane vesicle preparation
Membrane vesicles were prepared according to the procedure
described previously [39]. The membrane vesicle pellet was re-
suspended in a solution containing 10-mM Tris–HCl (pH 7.5), 250-
mM sucrose and 1× protease inhibitor cocktail (2 μg/ml aprotinine,
121 μg/ml benzamidine, 3.5 μg/ml E64, 1 μg/ml leupeptin and 50 μg/
ml Pefabloc). Aliquots of the membrane vesicles, after passage
through a Liposofast™ vesicle extruder (Avestin, Ottawa, Canada),
were stored in −80 °C.
2.6. Membrane vesicle transport
ATP-dependent LTC4 transport was assayed by a rapid ﬁltration
technique [39–41]. The assays were carried out in triplicate
determinations in a 30-μl solution containing 3 μg of membrane
proteins, 50-mM Tris–HCl (pH 7.5), 250-mM sucrose, 10-mM MgCl2
(or 10-mM MnCl2), 200-nM LTC4 (17.54 nCi of 3H-labeled LTC4) and
4-mM AMP (used as negative control) or 4-mM ATP (with an ATP
regenerating system consisting of 120 mU of creatine kinase and
10 mM of creatine phosphate). For percentage determination, above
components were mixed on ice, transferred to 37 °C water bath,
incubated at 37 °C for 4 min, brought back to ice and diluted with 1 ml
of ice-cold 1× transport buffer (50-mM Tris–HCl, pH 7.5, 250-mM
sucrose and 10-mMMgCl2). For kinetic analysis, the ATP solutions and
the membrane vesicles were prepared in two different eppendorf
tubes on ice, transferred to 37 °C heating block (ﬁlled with water),
warmed up to 37 °C, mixed the two solutions, incubated at 37 °C for
1 min, brought back to ice and diluted with 1 ml of ice-cold 1×
transport buffer.
2.7. Photoafﬁnity labeling of N-half and C-half of MRP1 protein
Vanadate preparation (from sodium orthovanadate) and photoafﬁ-
nity labeling of MRP1 protein were performed according to procedures
described previously [39,42,43]. Brieﬂy, photolabeling experiments
were carried out in a 10-μl solution containing 10 μg of membrane
proteins, 40-mM Tris–HCl (pH7.5), 2-mM ouabain, 10-mM MgCl2, 0.1-
mMEGTAandeither 10-μM[α-32P]-8-N3ATPor 10-μM[γ-32P]-8-N3ATP.
The other conditions, such as incubation time, temperature and
vanadate, are indicated in ﬁgure legend. After UV-irradiation
(λ=254 nm) on ice for 2 min, the labeled proteins were separated by
polyacrylamide gel (7%) electrophoresis and electro-blotted to a
nitrocellulose membrane.
2.8. Statistical analysis
The results in Figs. 1C and 4 and Tables 1 and S3 were presented as
means±SD from three independent experiments. The two-tailed P
values were calculated based on the unpaired t-test from GraphPad
Software Quick Calcs. By conventional criteria, if P value is less than
Fig. 1. Substitution of Q713 in Q-loop of NBD1 or Q1375 in Q-loop of NBD2 with an amino acid that eliminates the amide group did not have a signiﬁcant effect on the Mg·ATP-
dependent LTC4 transport. A. Linear amino acid sequences around the glutamine residue in Q-loop. The highlighted amino acids indicate the mutated residues. B. Expression of the
N-half and C-half of MRP1mutants in insect cells. Membrane vesicles were prepared from Sf21 cells infected with viral particles harboring pDual/NH/CH ofMRP1 cDNA. The amounts
(ng) of membrane proteins loaded in the gel are indicated on top of the gel. Molecular weight markers are indicated on the left. NH and CH on the right indicated the N-half and C-
half of MRP1 protein. C. Relative ATP-dependent LTC4 transport activities of the wt and mutated MRP1s. ATP-dependent LTC4 transport was performed according to the methods
described in Materials and methods. Since the amounts of MRP1 proteins determined in B were different, the amounts of membrane vesicles used in these experiments were
adjusted, based on the ratio of MRP1 protein in membrane vesicles listed in Table S2, to have a similar amount of MRP1 protein by adding varying amounts of membrane vesicles
prepared from insect cells infected with viral particles harboring pDual expression vector. For example, 1.56 μg of wt MRP1+1.44 μg of pDual and 3.00 μg of Q1375M were used to
determine the ATP-dependent LTC4 transport activities of wt MRP1 and Q1375M-mutated MRP1. The data, considering the transport activity catalyzed by wt MRP1 as 100%, are
presented as means±standard deviation of three independent experiments.
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statistically signiﬁcant.
3. Results
3.1. Substitution of Q713 in Q-loop of NBD1 or Q1375 in Q-loop of NBD2
with an amino acid that eliminates the amide group did not have a
signiﬁcant effect on the Mg·ATP-dependent LTC4 transport
In order to determine the functional role of the glutamine residue
in Q-loop of NBD1 or NBD2, the Q713 and Q1375 were substituted
with an asparagine (Fig. 1A) in the pDual construct expressing the N-
half and C-half of MRP1 simultaneously [37,38]. ATP-dependent LTC4
transport activity of each individual mutant, including Q713N andQ1375N, after adjusting the membrane vesicles to have similar
amount of MRP1 protein, based on the amount of protein shown in
Fig. 1B and the ratio listed in Table S2, is similar to that of wt MRP1
(Fig. 1C), indicating that the amide side group of asparagine with one
methylene shorter in asparagine than in glutamine plays a similar role
as that of glutamine. However, the ATP-dependent LTC4 transport
activity of the double mutant Q713N/Q1375N is signiﬁcantly lower
than that of wt MRP1 (Fig. 1C), implying that the double mutations
might signiﬁcantly affect the binding for Mg·ATP in both NBDs. We,
then, tested whether a mutant without the amide group would
signiﬁcantly reduce the ATP-dependent LTC4 transport. Interestingly,
substitution of the glutamine residue with a methionine, including
Q713M and Q1375M, increased the transport activities, whereas
substitution of the glutamine residue with a leucine, including Q713L
Table 1
Vmax (LTC4) and Km (Mg·ATP) values of wild-type and mutant MRP1s.
Construct Vmax (pmol/mg/min)a P value Km (μM Mg·ATP)* P value
Wt MRP1 104.3±20.5 65.7±4.2
Q713N 191.7±20.9 0.0135 318.3±2.4 0.0001
Q1375N 280.0±32.7 0.0030 370.0±8.2 0.0001
Q713N/Q1375N 63.7±6.9 0.0566 916.7±20.5 0.0001
Q713M 213.3±29.5 0.0128 278.3±19.3 0.0001
Q1375M 203.3±24.9 0.0123 295.0±7.1 0.0001
Q713M/Q1375M 77.0±12.5 0.1249 1006.3±12.7 0.0001
Q713L 120.0±4.1 0.3489 293.3±30.9 0.0005
Q1375L 390.0±24.8 0.0002 900.0±21.6 0.0001
Q713L/Q1375L 88.3±6.2 0.3505 970.0±80.0 0.0006
a Km (Mg·ATP) and Vmax (LTC4) values (n=3) for wild-type and Q713- or Q1375-
mutated MRP1 were derived from the corresponding Michaelis–Menten curves (with
variant concentration of ATP at 37 °C for 1 min). The P values for comparison of Vmax
(LTC4) and Km (Mg·ATP) of wild-type versus mutants are shown.
Fig. 2. Substitution of Q713 with an amino acid that eliminates the interaction of the
amide group (ε-oxygen) of glutamine residue in Q-loop with Mg++ cofactor
signiﬁcantly reduced Mg·ATP binding at NBD1. Photolabeling experiments were
carried out in the presence of 10 μM [γ-32P]-8-N3ATP on ice for 10 min. Molecular
weight markers (kDa) are indicated on the left. NH and CH on the right indicate the 32P-
labeled N-half and C-half of MRP1 protein.
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LTC4 transport (Fig. 1C). In contrast, the double mutants, including
Q713M/Q1375M and Q713L/Q1375L, signiﬁcantly decreased the ATP-
dependent LTC4 transport (Fig. 1C).
3.2. Substitution of the Q713 in NBD1 or Q1375 in NBD2 with an amino
acid that eliminates the interaction between this residue and Mg++
cofactor signiﬁcantly increased the Km value in ATP-dependent LTC4
transport
The results in Fig. 1C imply that the double mutants might
signiﬁcantly affect the binding of Mg·ATP. If this would be the case, it
meant that individual mutants, including Q713N, Q1375N, Q713M,
Q1375M, Q713L and Q1375L, should also decrease the binding of
Mg·ATP. We have found that decreased binding might signiﬁcantly
increase the Km (Mg·ATP) and Vmax values in ATP-dependent LTC4
transport [37,38]. To test whether thesemutants will also increase the
Km (Mg·ATP) and Vmax values, the same amount of MRP1 protein
used in Fig. 1C was employed to establish the Michaelis–Menten
curves. The results shown in Fig. S2 clearly indicate that the Vmax and
Km (Mg·ATP) values for Q1375L are signiﬁcantly higher than that for
wt MRP1. These experiments were repeated three times and the Vmax
and Km (Mg·ATP) values derived from these Michaelis–Menten
curves were listed in Table 1. The results in Table 1 indicate that the
Vmax values derived from Q713N, Q1375N, Q713 M, Q1375M and
Q1375L are signiﬁcantly higher than that of wt MRP1, whereas the
Vmax values of Q713L and the double mutants, including Q713N/
Q1375N, Q713M/Q1375M and Q713L/Q1375L, are not signiﬁcantly
different from that of wtMRP1. Interestingly, the Km (Mg·ATP) values
derived from all the mutants are signiﬁcantly higher than that of wt
MRP1 (Table 1). In addition, the Km (Mg·ATP) values derived from
the double mutants are signiﬁcantly higher than, except Q1375L, their
corresponding single mutants.
3.3. Substitution of the Q713 in NBD1 with an amino acid that
diminishes the interaction between this residue and Mg++ cofactor
signiﬁcantly decreased Mg·ATP binding at NBD1
The above results imply that all these mutants, regardless of
whether they are single mutants or double mutants, may signiﬁcantly
reduce the afﬁnity for Mg·ATP. In order to test this hypothesis, [γ-
32P]-8-N3ATP was used to label the NBD1 (within N-half) and NBD2
(within C-half) of MRP1 on ice by taking the advantage of expressing
these mutants in N-half and C-half so that we can check the effects of
these mutants on ATP binding or ADP-trapping directly without
partial trypsin digestion. Since [γ-32P]-8-N3ATP was used to label the
NBD1 and NBD2 of MRP1 on ice without vanadate, the labeling
reﬂects the Mg·ATP binding, but not ATP hydrolysis and vanadate-
dependent trapping. As shown in Fig. 2, the labeling at NBD2 (withinCH) is too weak to distinguish whether the mutations affect the
Mg·ATP binding or not. However, the labeling at NBD1 (within NH) is
high enough to distinguish whether the mutations affect the Mg·ATP
binding or not. As shown in Fig. 2, the mutations at NBD2, including
Q1375N, Q1375M and Q1375L, did not have a signiﬁcant effect on
Mg·ATP binding at NBD1, whereas the mutations at NBD1, including
Q713N, Q713N/Q1375N, Q713M, Q713M/Q1375M, Q713L and Q713L/
Q1375L, signiﬁcantly reduced the Mg·ATP binding at NBD1.3.4. Substitution of Q1375 with an amino acid that eliminates the
interaction of the amide side group (-oxygen) of glutamine residue in
Q-loop with Mg++ cofactor signiﬁcantly decreased the vanadate-
dependent Mg·ADP trapping at NBD2
Although the labeling at NBD2 was too weak to distinguish
whether the mutations would affect the Mg·ATP binding or not, the
above results imply that the mutations at NBD2 should also affect
Mg·ATP binding at NBD2. We have found that vanadate-dependent
ATP-hydrolysis-product ADP trapping mainly occurred at NBD2
[39,42]. In order to test whether the mutations at NBD2 would also
affect Mg·ATP binding and Mg·ADP trapping at NBD2, [γ-32P]-8-
N3ATP and [α-32P]-8-N3ATP were used to label the N-half and C-half
of MRP1 at 37 °C in the presence of vanadate. As shown in Fig. 3, [γ-
32P]-8-N3ATP, without UV treatment, labeled N-half and C-half of
MRP1, reﬂecting the phosphorylation events occurred in MRP1
protein [39]. However, upon treatment with UV, the labeling with
[γ-32P]-8-N3ATP at the NBD1 (within NH) is signiﬁcantly higher than
that without UV treatment, indicating that the bound [γ-32P]-8-N3ATP
at NBD1 is not efﬁciently hydrolyzed. The labeling at NBD2 (within
CH) with [γ-32P]-8-N3ATP, regardless of whether they were treated
with UV or not, was weak, suggesting that the bound ATP was
hydrolyzed. In contrast, the labeling at NBD2 with [α-32P]-8-N3ATP,
including wt MRP1, Q713N, Q713M, Q1375M, Q713M/Q1375M and
Q713L, is stronger than the corresponding labeling with [γ-32P]-8-
N3ATP, indicating that the bound Mg·ATP was hydrolyzed and
trapped there by vanadate. However, the labeling at the mutated
NBD2, including Q1375N, Q713N/Q1375N, Q1375M, Q713M/Q1375M,
Q1375L and Q713L/Q1375L, with [α-32P]-8-N3ATP was signiﬁcantly
lower than the corresponding labeling at wt MRP1, implying that
much less [α-32P]-8-N3ATP bound to the mutated NBD2 than to wt
MRP1 or the ATP-hydrolysis-product ADP had not been ﬁrmly trapped
there by vanadate.
Fig. 3. Substitution of Q713 or Q1375 with an amino acid that eliminates the interaction of the amide group (-nitrogen) of the glutamine residue in Q-loop with the putative
hydrolytic water molecule in the active center did not abolish ATP hydrolysis at NBD2. Photolabeling experiments were carried out in the presence of 0.8-mM vanadate and either
10 μM [α-32P]-8-N3ATP (α) or 10 μM [γ-32P]-8-N3ATP (γ) at 37 °C for 2 min. The reaction mixture was either loaded to the gel directly (−) or subjected to UV-irradiation (+) and
then loaded to the gel. Molecular weight markers (kDa) are indicated on the left. NH and CH on the right indicate the 32P-labeled N-half and C-half of MRP1 protein.
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activities of the Q-mutants
The above results were interpreted as that the glutamine residues
in Q-loops ofMRP1 participated in, via interactionwithmetal cofactor,
Mg·ATP binding, but did not play a crucial role in ATP hydrolysis and
in inter-domain communications between the NBDs and the TMDs. If
that would be the case, the double mutant Q713L/Q1375L might
require higher concentration of Mg++ to perform the ATP-dependent
LTC4 transport. To test this hypothesis, varying concentration ofMgCl2
was used to do the ATP-dependent LTC4 transport. As shown in Fig. S3,
wt MRP1 transported detectable amount of LTC4 into the membrane
vesicles at 0.5-mM MgCl2, whereas Q713L/Q1375L required 5-mM
MgCl2 to transport detectable amount of LTC4 into the membrane
vesicles. Substitution of the glutamine residue (with an amide side
group) at 713with asparagine (with an amide side group) signiﬁcantly
reduced the Mg·ATP binding at NBD1 (Fig. 2), suggesting that the
length of the side chain might also play an important role in Mg·ATP
binding. We wondered whether a bigger metal cofactor, for example,
Mn++ (with a radius of 0.80 Å) or Ca++ (0.99 Å) is bigger than Mg++
(0.66 Å), would increase the nucleotide binding of Q713N. Interest-
ingly, the Mn·ATP-dependent LTC4 transport activities of Q713N/
Q1375NandQ713M/Q1375Mwere signiﬁcantly higher than that ofwt
MRP1 (Fig. S4A), whereas the Ca·ATP-dependent LTC4 transport
activity of wt MRP1 was signiﬁcantly higher than that of the double
mutants (Fig. S4B). Due to these results, Mn·ATP and Mg·ATP were
used to establish Michaelis–Menten curves of wt MRP1. Interestingly,Fig. 4. MnCl2 signiﬁcantly enhanced the ATP-dependent LTC4 transport activities of the Q71
except that 10-mM MnCl2, instead of 10-mM MgCl2, was used in the transport assay.theKmvalue forMn·ATP (32.5 μM) is signiﬁcantly less than that of the
value for Mg·ATP (67.0 μM) and the Vmax value for Mn·ATP-
dependent LTC4 transport is also signiﬁcantly less than that for
Mg·ATP (Table S3), implying that MRP1 may have higher afﬁnity for
Mn·ATP than for Mg·ATP.
Mn·ATP was used to determine the LTC4 transport activities of wt
MRP1 and Q-mutants. Interestingly, the Mn·ATP-dependent LTC4
transport activity of Q713N or Q1375N is ~191% or 175% of wt MRP1
(Fig. 4), whereas the Mg·ATP-dependent LTC4 transport activity of
the corresponding mutant is ~81% or 83% of the wt MRP1 (Fig. 1C).
Strikingly, the Mn·ATP-dependent LTC4 transport activity of the
double mutant Q713N/Q1375N is ~162% of wt MRP1 (Fig. 4), whereas
theMg·ATP-dependent LTC4 transport activity of this mutant is ~33%
of the wt MRP1 (Fig. 1C). Similarly, the percentages (comparing to wt
MRP1 as shown in Fig. 4) of the Mn·ATP-dependent LTC4 transport
activities of other mutants, including Q713M, Q1375M, Q713M/
Q1375M, Q713L and Q1375L, are also signiﬁcantly higher than their
corresponding percentages (comparing to wt MRP1 as shown in
Fig. 1C) of the Mg·ATP-dependent LTC4 transport activities, suggest-
ing that thesemutantsmight have higher afﬁnity forMn·ATP than for
Mg·ATP. If that would be the case, at lower concentration of divalent
cation, wt MRP1 should have higher Mn·ATP-dependent LTC4
transport activity than that of Mg·ATP. Indeed, at 2-mM divalent
cation, the Mn·ATP-dependent LTC4 transport activity of wt MRP1 is
signiﬁcantly higher than that of Mg·ATP (Fig. S5), suggesting that the
glutamine residues in Q-loops of MRP1 contribute to ATP binding via
interaction with metal cofactor.3 or Q1375 mutants. The experiments were carried out exactly the same as in Fig. 1C,
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Structural analyses of several NBDs of ABC transporters suggested
that the conserved glutamine residue in Q-loop may interact: 1) with
Mg++ cofactor to participate inMg·ATP binding; 2) with the putative
hydrolytic water molecule in the active center to participate in ATP
hydrolysis; 3) with an amino acid from another NBD to stabilize the
NBD·ATP·ATP·NBD sandwich structure. In addition, the residues in
Q-loop form a cleft that interacts with the residues in L-loop of the
transmembrane subunits to play a role in transmitting the confor-
mational changes induced by ATP binding/hydrolysis from NBDs to
TMDs. However, the data derived from our studies indicate that the
glutamine residues in the Q-loops of MRP1 mainly play a role in
Mg·ATP binding, but not in ATP hydrolysis and in inter-domain
communications between the NBDs and the TMDs. This conclusion is
based on the facts that substitution of the Q713 in NBD1 or Q1375 in
NBD2 with an amino acid that eliminates the amide group: 1)
signiﬁcantly reduced the Mg·ATP binding at the mutated NBD1
(Fig. 2) or vanadate-dependent ADP trapping at the mutated NBD2
(Fig. 3); 2) did not abolish the Mg·ATP- (Fig. 1C) or Mn·ATP-
dependent (Fig. 4) LTC4 transport; 3) signiﬁcantly increased the Km
and Vmax values in ATP-dependent LTC4 transport (Table 1).
Of note, although substitution of the glutamine residues in Q-loops
of MRP1 signiﬁcantly decreased the afﬁnity for ATP, these mutations
signiﬁcantly increased the ATP-dependent LTC4 transport activities
(Figs. 1C and 4 and Table 1). These results were interpreted as that a
decreased afﬁnity for Mg·ATP and/or Mg·ATP hydrolysis product
Mg·ADP in these mutants might facilitate the release of the bound
nucleotide from the mutated NBDs and bring the molecule back to its
original conformation so that this protein can start a new cycle of ATP-
dependent solute transport [37,38,44].
Functional roles of the glutamine residue in Q-loop have also been
studied in other ABC transporters [45–47]. Substitution of the Q82 in
Q-loop of MalK, a bacterial maltose transporter, with either a lysine
(Q82K) or a glutamic acid (Q82E) reduced the ATPase activities to 61%
or 84% and maltose transport activities to 29% or 24% [46], indicating
that introducing a charged group at this position did not abolish the
ATP binding/hydrolysis and ATP-dependent maltose transport. Sub-
stitution of the Q88 in Q-loop of DrrA with a glutamic acid (Q88E)
reduced the level of ATP binding [45]. However, this mutation
retained the doxorubicin stimulated ATP binding [45], indicating that
this mutation did not abolish the inter-domain signal communication.
In contrast, however, substitution of the glutamine residue Q471 in Q-
loop of NBD1 or Q1114 in Q-loop of NBD2 in mouse P-gp with either a
glutamic acid or an alanine did not signiﬁcantly affect ATP binding, but
decreased the ATPase activities to ~10% [47], implying that the
interaction of the amide group of the glutamine residue in Q-loop
with the putative catalytic water molecule plays a crucial role for ATP
hydrolysis. Furthermore, the P-gp substrates, such as verapamil or
vinblastine, stimulated the ATPase activities of wt P-gp and the Q-
mutants. However, the substrate-stimulated ATPase activities of the
Q-mutants remained less than 10% of the wt P-gp [47], implying that
the glutamine residue in Q-loop of mouse P-gp may interact with the
putative hydrolytic water molecule in the active center to participate
in ATP hydrolysis. Based on these results, the authors concluded that
“the primary role of this glutamine residue is in inter-domain signal
communication.”
The results presented in this manuscript do not support the above
conclusion because the Mn·ATP-dependent LTC4 transport activities
of all Q-mutants, except Q713L/Q1375L, are signiﬁcantly higher than
that of wt MRP1 (Fig. 4). This might reﬂect the structural and
functional differences between the humanMRP1 and the mouse P-gp.
In other words, the glutamine residues in Q-loops of P-gp might
interact with the residues from intracellular loops of TMDs whereas
the glutamine residues in Q-loops of human MRP1 might not. To test
this possibility, we have established the nucleotide-free inward-facing (Fig. S6B) or the nucleotide-bound outward-facing (Fig. S6C)
MRP1 models and searched for the amino acids located within 4 Å of
Q713 or Q1375. Interestingly, we have not found any residue from
TMD1 or TMD2 that is located within 4 Å of Q713 or Q1375 (Tables S4,
S5 and S6), regardless of whether the nucleotide-free inward-facing
or the nucleotide-bound outward-facing model was used. In contrast,
many residues from intracellular loop 7 in TMD2, such as K1181 or
R1173, are located within 4 Å of the residues, such as E724, in Q-loop
of NBD1 (Table S5) and many residues from intracellular loop 5 in
TMD1, such as E521, are located within 4 Å of the residues, such as
S1381 (Table S6), in Q-loop of NBD2. Of note, the relative locations of
the residues may be changed in these two models. For example,
R1173 was located within 4 Å of E724 in Q-loop of NBD1 in the
nucleotide-free inward-facing model, whereas R1173 is not located
within 4 Å of E724, instead, K1181 is located within 4 Å of E724 in the
nucleotide-bound outward-facing model, perhaps reﬂecting the
conformational changes upon ATP binding. In fact, the distance
changes between a residue from the Q-loop (rather than the
glutamine residue itself) and a residue from an intracellular loop of
TMDs have been found in the nucleotide-free and nucleotide-bound
BmrA [48], a Bacillus ABC transporter. Thus, the interactions between
the residues listed in Tables S5 and S6, rather than the conserved
glutamine residues in Q-loops, may play a crucial role in inter-domain
signal communication in human MRP1.
Supplementarymaterials related to this article can be found online
at doi: 10.1016/j.bbamem.2011.02.004.
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